What's primary biliary cholangitis?
Primary biliary cholangitis is a long-term autoimmune liver disease in which the body's own immune system slowly destroys the small bile ducts inside the liver. As bile backs up (cholestasis), it can scar the liver over many years (fibrosis) and, if untreated, lead to cirrhosis. It mainly affects women and is usually found early from blood tests, often before symptoms appear.
| Also indexed as | ORPHA:186, MONDO:0005388 |
|---|---|
| Features mapped | 19 |
| Treatments mapped | 10 |
| Published sources | 20 |
| Last reviewed | 2026-08-04 |
Signs and symptoms
Antimitochondrial antibody positivity
A blood test for antimitochondrial antibodies (AMA) is positive in most people with this condition and is a key part of the diagnosis. Finding AMA together with a raised cholestatic liver enzyme is often enough to diagnose it without a liver biopsy.
Autoimmunity
This is an autoimmune condition, meaning the immune system mistakenly attacks the body's own tissue. Here it targets the small bile ducts inside the liver. Other autoimmune conditions often occur alongside it.
Antinuclear antibody positivity
Some antinuclear antibodies (ANA) found in the blood are specific to this condition, in particular ones called anti-gp210 and anti-sp100. They can help with diagnosis and give information about how the disease may behave.
Elevated gamma-glutamyltransferase level
Gamma-glutamyltransferase (GGT) is another liver enzyme linked to the bile ducts that is often raised in this condition. It can also carry information about how the disease is likely to progress.
Elevated circulating alkaline phosphatase concentration
A raised level of alkaline phosphatase (ALP), a liver enzyme linked to the bile ducts, is the usual first clue and is often picked up on a routine blood test before any symptoms. The response of ALP to treatment is also used to judge how well therapy is working.
Sleep disturbance
The itching of this condition can break up sleep, and the resulting tiredness and low mood add to the burden of the disease.
Portal hypertension
As PBC scars the liver, blood backs up in the veins feeding it, raising the pressure in the portal system (portal hypertension). In PBC this can sometimes begin even before full cirrhosis develops, and it drives complications like enlarged spleen and varices.
Xanthelasma
Because cholestasis raises blood cholesterol, people with PBC can develop soft yellowish cholesterol deposits in the skin, especially around the eyelids (xanthelasmas).
Jaundice
Jaundice, a yellowing of the skin and eyes from bile pigment building up, tends to appear in more advanced disease and is a sign to seek review.
Hepatic failure
If scarring of the liver advances far enough, the liver can begin to fail. Early diagnosis and treatment make this much less likely.
Biliary cirrhosis
Over many years, ongoing damage to the bile ducts can scar the liver into cirrhosis. With early diagnosis and treatment this outcome is now much less common, and the older name for the condition reflected this late stage rather than how most people present today.
Esophageal varix
When portal pressure rises in advanced PBC, veins at the lower end of the esophagus can swell into varices. These fragile veins can bleed, which is why they are watched for as the liver disease progresses.
Cirrhosis
If the disease is not controlled over many years, ongoing scarring can progress to cirrhosis and, rarely, liver failure. Early diagnosis and treatment make this outcome much less likely.
Abnormal intrahepatic bile duct morphology
The core problem is gradual destruction of the small bile ducts inside the liver. This injury blocks bile flow and drives the rest of the condition.
Osteoporosis
PBC interferes with the absorption and processing of nutrients the bones need, so thinning of the bones (osteoporosis) is a common complication. This raises the risk of fractures and is one reason bone health is monitored in PBC.
Increased circulating IgM concentration
Levels of an antibody type called immunoglobulin M (IgM) are often raised in this condition, which is one of its characteristic blood-test patterns.
Fatigue
Fatigue, a deep tiredness not fixed by rest, is the other most common symptom. It does not necessarily track with how advanced the liver disease is, and managing it is an important part of care.
Pruritus
Itching (pruritus) is one of the most common and troublesome symptoms. It can range from mild to severe and there are specific treatments that target it, so it is worth raising with the care team rather than enduring it.
Hyperpigmentation of the skin
Long-standing cholestasis in PBC can darken the skin (hyperpigmentation), often most noticeable in sun-exposed areas. It tends to appear alongside the itching and fatigue that are common in the disease.
How it is diagnosed
Primary biliary cholangitis
Diagnosed using: antimitochondrial antibody test.
“The presence of disease-specific serological antimitochondrial antibody (AMA) together with elevated alkaline phosphatase (ALP) as a biomarker of cholestasis is sufficient for…”
Primary biliary cholangitis
Diagnosed using: liver biopsy.
“Histopathology remains the definitive standard for diagnosing…”
Treatment and management
What the research describes, not a recommendation. Treatment decisions belong with your clinician.
This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.
ursodeoxycholic acid
Ursodeoxycholic acid (UDCA) is the first-line treatment and the foundation of care. Taken daily, it improves bile flow and liver blood tests and, started early, can give many people a normal life expectancy. About a third to 40% of people do not respond fully and are considered for additional, second-line therapy by a liver specialist.
Used to help with: Primary biliary cholangitis.
“…up to 40% of patients fail to achieve an adequate biochemical response to first-line ursodeoxycholic acid…”
obeticholic acid
Obeticholic acid is a licensed second-line treatment for people whose liver tests do not improve enough on ursodeoxycholic acid, or who cannot tolerate it. It is added on under a liver specialist's care. Its approval status has changed over time, so a specialist confirms whether it is currently an option.
Used to help with: Primary biliary cholangitis.
“…should be considered for second-line therapy, of which OCA is the only currently licensed National Institute for Health and Care Excellence recommended…”
fibrates
Fibrates (such as bezafibrate and fenofibrate) are used off-label, added on top of ursodeoxycholic acid, when liver tests have not responded well enough. Combining a fibrate with ursodeoxycholic acid lowers cholestatic liver markers more than ursodeoxycholic acid alone. They are given under specialist supervision because they can occasionally affect the liver.
Used to help with: Primary biliary cholangitis.
“Combination therapy of fibrates with UDCA significantly improved biochemical outcomes compared with UDCA…”
bezafibrate
Bezafibrate is a fibrate used off-label, added to ursodeoxycholic acid, for people whose liver markers (such as alkaline phosphatase) have not normalised. In studies of people already on ursodeoxycholic acid, continued bezafibrate was projected to reduce the chance of needing a liver transplant or dying from liver disease.
Used to help with: Primary biliary cholangitis.
“These findings highlight the potential clinical benefit of off-label BZF in UDCA-treated people without ALP…”
fenofibrate
Fenofibrate is a fibrate added to ursodeoxycholic acid for people whose response to ursodeoxycholic acid alone is not strong enough. In one cohort, adding fenofibrate improved liver blood tests and was linked to better transplant-free survival, though liver effects need to be watched for.
Used to help with: Primary biliary cholangitis.
“Fenofibrate add-on therapy improved not only biochemical responses but also long-term transplant-free survival in PBC patients with suboptimal response to…”
elafibranor
Elafibranor is one of the newer approved second-line treatments, added to ursodeoxycholic acid when the response to it is inadequate. As well as lowering alkaline phosphatase, it has shown promise for symptoms such as itching and fatigue that ursodeoxycholic acid does not treat.
Used to help with: Primary biliary cholangitis.
“Approved second-line therapies for PBC include elafibranor and seladelpar. Elafibranor and seladelpar were recently granted Food and Drug Administration (FDA)…”
seladelpar
Seladelpar is one of the newer approved second-line treatments, added to ursodeoxycholic acid when the response to it is inadequate. Alongside lowering alkaline phosphatase, it has shown promise for symptoms such as itching and fatigue.
Used to help with: Primary biliary cholangitis.
“Approved second-line therapies for PBC include elafibranor and seladelpar. Elafibranor and seladelpar were recently granted Food and Drug Administration (FDA)…”
cholestyramine
Cholestyramine is a bile acid sequestrant, usually the first medicine tried for the itching of this condition. It binds bile substances in the gut. It does not relieve every person's itch, so other options follow if it is not enough.
Used to help with: Primary biliary cholangitis.
“Patients often do not respond to conventional therapies such as cholestyramine, rifampicin, opioid antagonists, and…”
rifampicin
Rifampicin (also written rifampin) is used to treat the itching of this condition when a bile acid binder has not worked. In pooled trial data it significantly improved cholestatic itch. Liver and blood counts are monitored while it is used.
Used to help with: Primary biliary cholangitis.
“…rifampin and nalfurafine hydrochloride both significantly improved…”
liver transplantation
Liver transplantation is the treatment for end-stage liver disease when the condition has progressed despite medicines. Most people never reach this point if treated early. The condition can sometimes come back in the transplanted liver over the years that follow.
Used to help with: Primary biliary cholangitis.
“Liver transplantation (LT) is the only treatment option for end-stage liver…”
How to read the evidence labels
Where this comes from
This guide is built from 20 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.
Take it further
Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.